One MicroRNA, Two Missions: Duplex From Pre-miR-16 Strikes Both VEGF and Hypoxia Pathways in Lung Cancer

Anti-angiogenic therapy has long been one of the most seductive ideas in oncology: starve a tumor of its blood supply and it will wither. Yet in lung cancer, the clinical reality has repeatedly fallen short of that promise. A new study published in Cell Death Discovery by Yuzhe Wang, Wenyu Xue, and colleagues at the Moscow Center for Advanced Studies and the Russian Academy of Sciences offers a detailed mechanistic explanation for why blocking a tumor’s vascular supply so often produces only temporary benefit, and it proposes an elegant molecular solution drawn from one of the cell’s own regulatory molecules.

The team focused on non-small cell lung cancer (NSCLC), the most common form of lung malignancy, and on bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGFA), the master signal that tumors use to recruit new blood vessels. Bevacizumab does suppress neovascularization, but its benefit is frequently transient. The researchers set out to determine what the tumor does in response to this blockade, and the answer they uncovered is a classic example of biological compensation: the very act of cutting off the oxygen supply activates a survival program that helps the tumor adapt and evade the therapy.

Using human NSCLC cell systems, the investigators showed that inhibiting VEGFA paradoxically intensifies intratumoral hypoxia, the oxygen-starved state that develops when vessels fail to keep pace with tumor growth. Hypoxia is not merely a passive consequence of poor blood supply; it is a potent signaling condition. Under low oxygen, the transcription factor HIF1A is stabilized and accumulates in the nucleus, where it switches on a battery of genes that promote malignancy. In their experiments, VEGFA inhibition was consistently accompanied by an upregulation of HIF1A, and elevated HIF1A in turn drove measurable increases in tumor cell migration, epithelial-to-mesenchymal transition (the process by which stationary epithelial cells acquire the motile, invasive traits of mesenchymal cells), and resistance to cisplatin, a mainstay chemotherapy drug for lung cancer.

Perhaps the most consequential discovery concerns CD105, also known as Endoglin. The study found that HIF1A upregulates CD105, a hypoxia-responsive pro-angiogenic mediator expressed on proliferating endothelial cells. In practical terms, this means that when bevacizumab blocks VEGFA and the tumor becomes hypoxic, the resulting HIF1A surge pushes endothelial cells toward CD105-dependent vessel formation, an alternative angiogenic route that the antibody does not touch. The researchers describe this as a hypoxia-driven HIF1A-CD105 axis that sustains tumor aggressiveness and vascular adaptation despite continued VEGFA blockade. It is a molecular account of why anti-angiogenic therapy so often buys time rather than cures: the treatment itself creates the conditions for vascular escape.

Having identified the resistance circuit, the team went looking for a way to disable both of its nodes at once, and they found it in an unexpected place: the precursor of a naturally occurring microRNA. MicroRNAs are short regulatory RNA molecules that fine-tune gene expression by binding complementary sequences in target messenger RNAs and repressing their translation or stability. Most microRNAs are produced from hairpin-shaped precursors, and the canonical model treats one strand of the resulting duplex as the functional guide strand while the other, the passenger strand, is discarded as waste. The pre-miR-16-1 hairpin defies this simplification, and the new study demonstrates that both of its strands carry therapeutic information.

The guide strand, miR-16-5p, directly represses VEGFA, functionally recapitulating the anti-angiogenic action of bevacizumab but at the level of gene expression rather than protein neutralization. The passenger strand, miR-16-1-3p, performs an entirely different and complementary task: it suppresses HIF1A expression itself, preventing the hypoxia-induced malignant program from ever being switched on and, as a downstream consequence, limiting the upregulation of CD105. In other words, a single duplex derived from a physiological microRNA precursor contains, in its two strands, a coordinated attack on both the angiogenic engine and the adaptive hypoxic feedback that ordinarily undermines anti-angiogenic drugs.

The functional analyses underpinning this claim were systematic. When the researchers inhibited VEGFA alone, they observed the expected rise in HIF1A along with the associated malignant phenotypes: enhanced migration, mesenchymal-like morphological changes, and increased cisplatin resistance. When they co-expressed miR-16-1-3p, HIF1A levels fell and these adverse phenotypes were attenuated. This strand-by-strand dissection establishes causality rather than mere correlation: the passenger strand is not a passive byproduct of microRNA biogenesis but an active suppressor of the hypoxic response, and its inclusion is what converts a one-target intervention into a two-target one.

The decisive test came in vivo. Using the chick chorioallantoic membrane (CAM) xenograft model, a widely used platform in which human tumor cells are grafted onto the vascularized membrane of a chick embryo, the team compared single anti-angiogenic intervention with the dual regulatory approach. The results were striking. Dual regulation of VEGFA and HIF1A markedly reduced vascular density, tumor growth, and metastatic dissemination compared with blocking VEGFA alone. The reduction in metastatic burden is particularly noteworthy, because it suggests that suppressing the hypoxic response does more than improve vascular control; it also removes a key driver of the invasive and migratory behavior that allows cancer cells to seed distant sites.

The broader significance of the work lies in its reframing of anti-angiogenic resistance. Rather than treating resistance as an accident of tumor evolution, the study characterizes it as a predictable, pathway-level consequence of therapy: block VEGFA, induce hypoxia, stabilize HIF1A, upregulate CD105, and the tumor rebuilds its blood supply through a route the drug cannot reach. This logic suggests that the therapeutic window for anti-angiogenic treatment in NSCLC could be substantially widened by pairing VEGFA suppression with simultaneous HIF1A inhibition, and the pre-miR-16-1 duplex provides a proof of concept for how that pairing might be achieved with a single physiological molecule.

There are, of course, distance markers between a chick embryo membrane and the clinic. Delivering RNA duplexes reliably to tumor cells in human patients remains a formidable challenge, and the safety profile of simultaneously suppressing HIF1A, a transcription factor with normal roles in physiology, will require careful evaluation. Nevertheless, the study establishes a clear mechanistic framework and a candidate dual-regulatory agent grounded in the cell’s own RNA biology. By showing that the two strands of a single microRNA precursor can cooperate to strike both the VEGF pathway and the hypoxic feedback loop that rescues it, the researchers have turned a discarded passenger strand into a potential therapeutic partner, and they have given the field a concrete strategy for making anti-angiogenic therapy in lung cancer live up, at last, to its original promise.

Subject of Research: Dual targeting of VEGFA and HIF1A pathways by the pre-miR-16-1 microRNA duplex to overcome anti-angiogenic therapy resistance in non-small cell lung cancer

Article Title: Harnessing the cooperative function of duplex from pre-miR-16 hairpin to simultaneously inhibit VEGF and hypoxia pathways in human non-small cell lung cancer

Article References: Wang, Y., Xue, W., Malakhov, P. A., Smirnova, A. V., Pustovalova, M., Kuzmin, D. V., & Leonov, S. (2026). Harnessing the cooperative function of duplex from pre-miR-16 hairpin to simultaneously inhibit VEGF and hypoxia pathways in human non-small cell lung cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03392-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03392-5

Keywords: non-small cell lung cancer, anti-angiogenic therapy, bevacizumab, VEGFA, HIF1A, hypoxia, CD105, Endoglin, miR-16, microRNA duplex, epithelial-mesenchymal transition, chemoresistance